ArticleEuropean journal of clinical pharmacology2018
The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects.
Article in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Quercetin as a modulator of xenobiotic metabolism: integrating CYP450 regulation, phase II conjugation pathways, and transporter-mediated drug interactions.European journal of clinical pharmacology · 2026Pooled it
- Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.British journal of clinical pharmacology · 2019Trial
- Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Organic solvent-free micellar liquid chromatographic determination of amoxicillin, chlorzoxazone, and ibuprofen in pharmaceutical and biological matrices.Scientific reports · 2026Article
- Review
- Stat4 rs7574865 polymorphism promotes the occurrence and progression of hepatocellular carcinoma via the Stat4/CYP2E1/FGL2 pathway.Cell death & disease · 2022Article
- Mechanistic Basis for the Role of Phytochemicals in Inflammation-Associated Chronic Diseases.Molecules (Basel, Switzerland) · 2022Review
- Article
- Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo.Pharmaceutics · 2021Article
- Mango (Molecules (Basel, Switzerland) · 2021Review
- Article
- Porcine cytochrome 2A19 and 2E1.Basic & clinical pharmacology & toxicology · 2019Review
- Regulation of X-Ray Irradiation on the Activity and Expression Levels of CYP1A2 and CYP2E1 in Rats.Frontiers in pharmacology · 2019Article
- In vitro inhibitory effects of bergenin on human liver cytochrome P450 enzymes.Pharmaceutical biology · 2018Article
- Similar effect of quercetin on CYP2E1 and CYP2C9 activities in humans?European journal of clinical pharmacology · 2018Article
- Response: Similar effect of quercetin on CYP2E1 and CYP2C9 activities in humans?European journal of clinical pharmacology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purposePrevious in vitro studies have demonstrated that quercetin inhibits CYP2E1 enzyme, but there are no available data to indicate that quercetin inhibits CYP2E1 enzyme in humans. The purpose of the present study was to assess the effect of quercetin on CYP2E1 enzyme activity in healthy subjects using chlorzoxazone (CHZ) as a CYP2E1 substrate.
methodsAn open-label, two-period, sequential study was conducted in 12 healthy subjects. A single dose of CHZ 250 mg was given to subjects during control phase and after treatment phases. Quercetin at a dose of 500 mg was given to subjects twice daily for a period of 10 days. The blood samples were collected at predetermined time intervals after CHZ dosing and analyzed to determine the concentrations of CHZ and 6-hydroxychlorzoxazone (6-OHCHZ).
resultsTreatment with quercetin significantly enhanced the maximum plasma concentration (C
conclusionsThe results suggest that altered pharmacokinetics of CHZ might be attributed to quercetin-mediated inhibition of CYP2E1 enzyme. Further, the inhibition of CYP2E1 by quercetin may represent a novel therapeutic approach for minimizing the ethanol-induced CYP2E1 enzyme activity and results in reduced hepatotoxicity of ethanol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.